Catalyst Dossier · compiled by CeliA 🧫

MOLECULAR PARTNERS AG (MOLN)

Biological Products, (No Diagnostic Substances) · market cap $148M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-24

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-24Earningsimp 5/10
2026-09-15 (est.)Phase 2 · PMD-026imp 7/10

Pipeline

Asset	Phase	Indication
MP0250	Phase 2	Neoplasms
ensovibep	Phase 2	Covid19
MP0250 plus BOR+DEX	Phase 2	Multiple Myeloma in Relapse
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1	Phase 2	Leukemia
[212Pb]Pb-MP0712	Phase 2	Large Cell Neuroendocrine Carcinoma
4D-310	Phase 2	Fabry Disease
ATL-001 (Ciclopirox oral solution)	Phase 2	Congenital Erythropoietic Porphyria (CEP)
PMD-026	Phase 2	Metastatic Breast Cancer

Price & technical context

3-month

-0.6%

6-month

-7.4%

12-month

+7.3%

52-wk range

$3.47–$5.13

vs 50-day MA

-1.1%

vs 200-day MA

-4.6%

Realized vol

56.8%

Max drawdown

-68.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MOLN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.